Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
121
days
Event-free survival in patients with early triple-negative breast cancer receiving platinum-free, de-escalated anti-PD-1 neoadjuvant therapy: an updated analysis of the NeoTENNIS trial
Authors
Shuang Hao; Xuliren Wang; Lin-Xiaoxi Ma; Min He; Bingqiu Xiu; Benlong Yang; Jiajian Chen; Xiaoyan Huang; Qin Xiao; Yan Huang; Ruo-Hong Shui; A-Yong Cao; Jun-Jie Li; Gen-Hong Di; Wen-Tao Yang; Guang-Yu Liu; Ke-Da Yu; Yi-Zhou Jiang; Zhong-Hua Wang; Zhi-Ming Shao; Jiong WuShow moreShow less
Affiliations
Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China; Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, ChinaShow moreShow less
199
days
CHK1/2 as a potential therapeutic target in Neurofibromatosis type 2 schwannomas
Authors
Dorothy Benton; Ramil Khusnutdinov; Mariia Buts; Mariia Dmitrieva; Daniela Araiza-Olivera; Cristina Uribe-Alvarez; Jonathan ChernoffShow moreShow less
Affiliations
Cancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, United States of America; Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, United States of America; Medical Faculty No. 1, Bogomolets National Medical University, Kyiv, UkraineShow moreShow less
85
days
Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for clinical trial design
Authors
Kyle P. Gribbin; Hen Halamish; Ivan Rodriguez Siordia; Jennifer M. Finan; Michael J. Pishvaian; Charles D. Lopez; Adel Kardosh; Shaun Goodyear; Rosalie C. Sears; Teresa Zimmers; Aaron Grossberg; Katelyn T. Byrne; Jonathan R. BrodyShow moreShow less
Affiliations
Department of Surgery, Oregon Health & Science University, Portland, OR, USA; Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; Brenden-Colson Center for Pancreatic Care, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; Division of Hematology Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA; Department of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, OR, USA; Department of Radiation Medicine, Oregon Health & Science University, Portland, OR, USA; Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USAShow moreShow less
162
days
A simplified scoring system for predicting total hip arthroplasty in hematologic cancer patients with osteonecrosis of the femoral head following allogeneic hematopoietic stem cell transplantation
Authors
Yun He; Peng Zhao; Yejun Wu; Bo Yang; Hu Li; Ke Tao; Tiezheng Sun; Jianhao Lin; Haixia Fu; Qiusha Huang; Xiaolu Zhu; Fengrong Wang; Xiaodong Mo; Yuanyuan Zhang; Wei Han; Huan Chen; Yao Chen; Jun Kong; Zhidong Wang; ChenHua Yan; Jingzhi Wang; Tingting Han; Yuhong Chen; Yuqian Sun; Yingjun Chang; Yu Wang; Lanping Xu; Xiaojun Huang; Xiaohui ZhangShow moreShow less
Affiliations
Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China; National Clinical Research Center for Hematologic Disease, Beijing, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Collaborative Innovation Center of Hematology, Peking University, Beijing, China; Peking University People's Hospital, Arthritis Clinical and Research Center, Beijing, ChinaShow moreShow less
153
days
MCM10 modulates lipid metabolic reprogramming via the USP7-FASN axis to accelerate renal cell carcinoma progression
Authors
Ashuai Du; Kehua Jiang; Kai Li; Xinpei Deng; Dongbo Yuan; Yuanyuan Luo; Songsong Tan; Xuchao Dai; Bo Yu; Bo Yan; Huichao Huang; Junjie Xu; Yanjun Wang; Jianguo ZhuShow moreShow less
Affiliations
Department of Infection, Guizhou Provincial People's Hospital, Guiyang, 550000, China; Guangzhou Medical University, Guangzhou, 511495, China; Department of Urology, Guizhou Provincial People's Hospital, Key Laboratory for Cancer Prevention and Treatment of Guizhou Province, Guiyang, 550000, China; Guizhou University Medical College, Guiyang, 550025, China; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Zunyi Medical University, Zunyi, 563000, China; Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Hunan, ChinaShow moreShow less
190
days
PRMT1 and YBX1 cooperatively transcriptionally activate GPX4 to inhibit ferroptosis and promote breast cancer progression
Authors
Yu Li; Baowen Yuan; Jiaxiang Liu; Xin Wang; Jingyao Zhang; Ting Hu; Tianyu Ma; Die Zhang; Yinuo Wang; Jingjing Zhang; Jiayi Gao; Tianyang Gao; Xinhui Hao; Chang Guo; Dong Yan; Wei Huang; Yan WangShow moreShow less
Affiliations
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, China; Institute of Cancer Research, Henan Academy of Innovations in Medical Sciences, Zhengzhou, Henan, ChinaShow moreShow less
FAQ
How long does CANCER LETTERS take to review a manuscript?
As of 2026-11-19, CrushSCI has 16 complete review records for CANCER LETTERS. The fastest paper went from submission to acceptance in 52 days (ACSL5 drives pancreatic ductal adenocarcinoma by suppressing mitophagy and enhancing ferroptosis resistance via the JAK1-STAT1-OASL axis, received 2026-07-06, accepted 2026-08-27); the slowest took 267 days. The average is 153.5 days and the median is 154 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
